ACT Share Price

Open 251.10 Change Price %
High 251.10 1 Day 0.00 0.00
Low 251.10 1 Week -0.15 -0.06
Close 251.10 1 Month 0.95 0.38
Volume 30 1 Year 109.10 76.83
52 Week High 266.90
52 Week Low 125.25
ACT Important Levels
Resistance 2 251.10
Resistance 1 251.10
Pivot 251.10
Support 1 251.10
Support 2 251.10
ETR Germany Most Active Stocks
CBK 9.28 -0.22%
CBK 9.28 -0.22%
DBK 14.90 -1.00%
DBK 14.90 -1.00%
EOAN 8.90 -1.44%
EOAN 8.90 -1.44%
RWE 19.07 -2.90%
RWE 19.07 -2.90%
DTE 16.66 -0.18%
DTE 16.66 -0.18%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
FAC 0.27 17.39%
FAC 0.27 17.39%
FAC 0.27 17.39%
5M71 39.00 13.70%
DTD2 6.00 12.36%
NK2A 0.10 11.11%
USE 0.20 11.11%
AR2 8.01 10.94%
FAM1 1.20 10.09%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
WI4 0.74 -48.61%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
AYO 0.02 -33.33%
4SL 0.32 -11.11%
NN6 1.60 -11.11%
MWB 3.78 -10.00%
More..

Actelion Ltd (ETR: ACT)

ACT Technical Analysis 2
As on 20th Jun 2017 ACT Share Price closed @ 251.10 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 196.33 & Sell for SHORT-TERM with Stoploss of 256.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACT Target for June
1st Target up-side 259.7
2nd Target up-side 264.36
3rd Target up-side 269.02
1st Target down-side 246.4
2nd Target down-side 241.74
3rd Target down-side 237.08
ACT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.actelion.com
ACT Address
ACT
Gewerberstrasse 16
Allschwil, 4123
Switzerland
Phone: 41 61 565 65 65
Fax: 41 61 565 65 00
ACT Latest News
Interactive Technical Analysis Chart Actelion Ltd ( ACT ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Actelion Ltd
ACT Business Profile
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; Opsumit, an orally available endothelin receptor antagonist; and Valchlor, a chemotherapeutic agent for the treatment of mycosis fungoides, a common type of cutaneous T-cell lymphoma. The company also provides Veletri, a formulation of epoprostenol for the treatment of PAH; Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Japan, China, Russia, and Mexico. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.